<?xml version="1.0" encoding="UTF-8"?>
<ref id="R57">
 <label>57.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Flinn</surname>
    <given-names>IW</given-names>
   </name>
   <name>
    <surname>Hillmen</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Montillo</surname>
    <given-names>M</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL</article-title>. 
  <source>
   <italic toggle="yes">Blood.</italic>
  </source>
  <year>2018</year>;
  <volume>132</volume>:
  <fpage>2446</fpage>â€“
  <lpage>2455</lpage>.
  <pub-id pub-id-type="pmid">30287523</pub-id>
 </mixed-citation>
</ref>
